Abstract:Background: Numerous clinical studies have validated plasma EBV DNA as a reliable biomarker for nasopha-ryngeal carcinoma (NPC) screening, tumor load monitoring, and prognosis prediction in endemic regions. However, the clinical relevance of plasma EBV DNA as a biomarker for NPC in non-endemic areas is still unclear.Method: The pretreatment plasma EBV DNA of 1405 newly diagnosed NPC patients from three major regional hospitals in non-endemic areas were analyzed retrospectively. The medical records of 244 age-and gender-matched healthy individuals were reviewed. EBV DNA was detected using Polymerase Chain Reaction (PCR). Based on the baseline of 400 and 0 copies/mL, the distribution characteristics of the pretreatment EBV DNA load in different clinical stages and geographic regions were analyzed. The diagnostic value of pretreatment plasma EBV DNA for NPC with two baselines was evaluated using the ROC curve.Results: NPC patients had a significantly higher pretreatment EBV DNA level than healthy controls (P<0.001). Pretreatment EBV DNA was closely associated with clinical and TNM stages in non-endemic areas, as it was in endemic areas. However, when 400 copies/mL set as the detection baseline, the sensitivity and specificity for NPC diagnosis were 40.8 % and 100 %, respectively (AUC = 0.704, cut off = 200.5 copies/mL). This sensitivity was lower than that reported in endemic regions (41.5 % -97.1 %). Lower sensitivity may result in false negatives, missing diagnoses during NPC screening. Further investigation revealed that 39.7 % (558/1405) of NPC patients had detectable EBV DNA and S amplification curves. Optimizing the detection limit to 0 copies/mL, the sensitivity could be improved to 80.5 % (AUC = 0.901).Conclusions: In non-endemic areas, the clinical significance of plasma EBV DNA as a biomarker for NPC was restricted due to the low detection limit of 400 copies/mL. More efficient nucleic acid extraction and detection methods are needed to optimize the detection limit and increase the clinical application of plasma EBV DNA for NPC.

Design of InnoPrimers-Duplex Real-Time PCR for Detection and Treatment Response Prediction of EBV-Associated Nasopharyngeal Carcinoma Circulating Genetic Biomarker

[Detection of EBV-LMP1 antibodies in sera and clinical significance in the patients with nasopharyngeal carcinoma].

Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma

A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma

Establishment and validation of circulating cell-free DNA signatures for nasopharyngeal carcinoma detection

Evaluation of Circulating EBV Microrna BART2‐5p in Facilitating Early Detection and Screening of Nasopharyngeal Carcinoma

Serological profiling using an Epstein-Barr virus mammalian expression library identifies EBNA1 IgA as a pre-diagnostic marker for nasopharyngeal carcinoma

Clinical Relevance of Plasma EBV DNA As a Biomarker for Nasopharyngeal Carcinoma in Non-Endemic Areas: A Multicenter Study in Southwestern China

Nasopharyngeal Carcinoma Risk Prediction Via Salivary Detection of Host and Epstein-Barr Virus Genetic Variants

Integrating Pre- and Post-Treatment Plasma Epstein-Barr Virus DNA Levels for Better Prognostic Prediction of Nasopharyngeal Carcinoma

CRISPR Cas12a-mediated Amplification-Free Digital DNA Assay Improves the Diagnosis and Surveillance of Nasopharyngeal Carcinoma.

Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma

Utility of Epstein–Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs

Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma

The initial results of Epstein-Barr virus-encoded latent membrane protein-1 for screening nasopharyngeal carcinoma

Advances of Biomarkers in Nasopharyngeal Carcinoma's Early Detection.

Circulating Epstein‒Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma

Evaluation of Plasma Epstein‐Barr Virus DNA Load to Distinguish Nasopharyngeal Carcinoma Patients from Healthy High‐risk Populations in Southern China

Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival

Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA As a Prediagnostic Marker for Nasopharyngeal Carcinoma

Plasma Epstein-Barr virus microRNA BART8-3p as a potential biomarker for detection and prognostic prediction in early nasopharyngeal carcinoma